Hukkanen Renee R, Irizarry Armando, Fikes James D, Schafer Kenneth A, Boyle Molly H
42372Eisai, Inc., Cambridge, MA, USA.
7092Eli Lilly and Company, Indianapolis, IN, USA.
Toxicol Pathol. 2020 Dec;48(8):944-948. doi: 10.1177/0192623320964087. Epub 2020 Oct 12.
The coronavirus disease 2019 pandemic has affected business on numerous fronts in unprecedented and abrupt ways. From site closures and local "stay-at-home orders" to travel advisories and restrictions, the day-to-day practice of toxicologic pathology has been impacted dramatically and rapidly. A critical function of Toxicologic Pathologists is performing pathology peer review for nonclinical studies. Traditionally, corroborating the findings of histological assessment could be achieved through shipment of histopathological slides to the peer review pathologist, or by the peer review pathologist traveling to the location of the slides (eg, the test facility). Since early 2020, many pathologists have been unable to perform the latter due to local, regional, national, test facility, company, and/or personal restrictions. The disruption for some has been minimal, while others are working from home for the first time. We recommend that contingency plans for all peer review procedures and personnel should be in-place to accommodate sudden and unexpected workflow transitions. Now, more than ever, approaching peer reviews with enhanced adaptability will help ensure success.
2019年冠状病毒病大流行以前所未有的突然方式在众多方面影响了业务。从场所关闭和当地“居家令”到旅行建议和限制，毒理病理学的日常工作受到了巨大而迅速的影响。毒理病理学家的一项关键职能是对非临床研究进行病理学同行评审。传统上，通过将组织病理学切片运送给同行评审病理学家，或由同行评审病理学家前往切片所在地（如测试机构），可以实现对组织学评估结果的确认。自2020年初以来，由于当地、地区、国家、测试机构、公司和/或个人限制，许多病理学家无法进行后者。对一些人来说，干扰很小，而另一些人则首次在家工作。我们建议应为所有同行评审程序和人员制定应急计划，以适应突然和意外的工作流程转变。现在，比以往任何时候都更需要以更强的适应能力进行同行评审，这将有助于确保成功。
